ON THE SIGNIFICANCE OF THE SCORE-2 RISK SCALE FOR CARDIOVASCULAR COMPLICATIONS AMONG PATIENTS WITH PREDIABETES
Abstract
The aim of the study is to consider and evaluate the value of the SCORE-2 cardiovascular risk scale among patients with prediabetes. Material and methods of the study. The study included 45 people aged 40 to 65 years, including 25 men with an average age of 59.3±8.2 years and 20 women with an average age of 55.2±7.1 years. The control group consisted of 20 healthy people. Research methods: included general clinical methods, biochemical tests (fasting blood glucose level and 2 hours after a meal, glycated hemoglobin, bilirubin, both direct and indirect, ALT, AST, PTI, coagulogramm, C-reactive protein, urea, creatinine, lipid spectrum), hormonal studies (if necessary, insulin and C-peptide levels in the blood) and instrumental methods: ECG, ultrasound of the endocrine glands and internal organs, chest X-ray and others. Research results. When assessed using the SCORE2 scale, patients were divided into risk groups: 17 of them were in the low risk group, 15 in the moderate risk group, 7 in the high risk group and 6 in the very high risk group. The estimated risk of death and non-fatal CVD ranged from 0.3% to 53.2%, with a mean value of 8.8±7.5%. According to the SCORE2 scale, all patients were classified into the high and very high risk categories, comprising 18 and 27 patients, respectively. Conclusions. 1. The SCORE2 scale, used to calculate non-high-density lipoprotein cholesterol (non-HDL-C) levels, provides a more individualized risk assessment, showing more unfavorable results among the Uzbek ethnic group. The SCORE2 system has a more differentiated approach to determining individual cardiovascular risk.
About the Authors
List of references
Chipayo-Gonzales D, Ramakrishna H, Nuñez-Gil IJ. Score2: A New Updated Algorithm to Predict Cardiovascular Disease Risk in Europe. J Cardiothorac Vasc Anesth. 2022 Jan;36(1):18-21. doi: 10.1053/j.jvca.2021.09.033.
SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-2454. doi: 10.1093/eurheartj/ehab309.
Armstrong K, Berlin M, Schwartz JS, Propert K, Ubel PA. Barriers to influenza immunization in a low-income urban population. Am J Prev Med. 2001 Jan;20(1):21-5. doi: 10.1016/s0749-3797(00)00263-4.
Huang Y, Huang W, Mai W, Cai X, An D, Liu Z, Huang H, Zeng J, Hu Y, Xu D. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017 Apr;35(4):677-688. doi: 10.1097/HJH.0000000000001226
Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. https://doi.org/10.1136/bmj.m2297.
Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953. https://doi.org/10.1136/bmj.i5953.
Sinha A, Ning H, Ahmad FS, et al. Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project. Cardiovasc Diabetol. 2021;20(1):66. https://doi.org/10.1186/s12933-021-01265-y.
Cai X, Liu X, Sun L, He Y, Zheng S, Zhang Y, et al. Prediabetes and the risk of heart failure: a meta-analysis. Diabetes Obes Metab. 2021. https://doi.org/10.1111/dom.14388.
Pandey A, Vaduganathan M, Patel KV, Ayers C, Ballantyne CM, Kosiborod MN, et al. Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. JACC Heart Fail. 2021;9(3):215–23. https://doi.org/10.1016/j.jchf.2020.10.013.
Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452–61. https://doi.org/10.1016/S2213-8587(19)30093-2.
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.